Marguerite Koutsoukos

3.8k citations

29 papers · 1.8k indexed · 1 hit paper · h-index 18

Co-authors: Gérald Voss Paul A. Goepfert David C. Montefiori Jesus F. Salazar-Gonzalez Xiping Wei Julie M. Decker John R. Mascola Miroslawa Bilska
Topics: HIV Research and Treatment (18 papers)Immune Cell Function and Interaction (10 papers)vaccines and immunoinformatics approaches (7 papers)
Cited by: Virology Immunology Infectious Diseases
Journals: Nature CommunicationsSHILAP Revista de lepidopterologíaPLoS ONE
Partner nations: Belgium United States United Kingdom

In The Last Decade

Marguerite Koutsoukos

28 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Immunodeficiency Virus Type 1envClones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

2005 845 citations Marguerite Koutsoukos, Gérald Voss et al. profile →

Peers

Countries citing papers authored by Marguerite Koutsoukos

Since Specialization

Citations

This map shows the geographic impact of Marguerite Koutsoukos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marguerite Koutsoukos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marguerite Koutsoukos more than expected).

Fields of papers citing papers by Marguerite Koutsoukos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marguerite Koutsoukos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marguerite Koutsoukos. The network helps show where Marguerite Koutsoukos may publish in the future.

Co-authorship network of co-authors of Marguerite Koutsoukos

This figure shows the co-authorship network connecting the top 25 collaborators of Marguerite Koutsoukos. A scholar is included among the top collaborators of Marguerite Koutsoukos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marguerite Koutsoukos. Marguerite Koutsoukos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters 2023 ·SHILAP Revista de lepidopterología ·Catherine Berry,Vincent Pavot,Natalie G. Anosova,Michael Kishko,Lu Li,(unknown),Alice Raillard,(unknown),(unknown),Dinesh S. Bangari,Swagata Kar,Caroline Atyeo,Yixiang Deng,Galit Alter,Cindy Gutzeit,Marguerite Koutsoukos,Roman M. Chicz,Valérie Lecouturier	2
2	Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates 2023 ·Nature Communications ·Vincent Pavot,Catherine Berry,Michael Kishko,Natalie G. Anosova,Lu Li,(unknown),De-An Huang,Alice Raillard,(unknown),Cindy Gutzeit,Marguerite Koutsoukos,Roman M. Chicz,Valérie Lecouturier	12
3	Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates 2022 ·Nature Communications ·Vincent Pavot,Catherine Berry,Michael Kishko,Natalie G. Anosova,De-An Huang,(unknown),Alice Raillard,(unknown),Cindy Gutzeit,Marguerite Koutsoukos,Roman M. Chicz,Valérie Lecouturier	25
4	Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination 2020 ·Vaccine ·Olivier Van Der Meeren,Erik Jongert,Kelly E. Seaton,Marguerite Koutsoukos,Annelies Aerssens,(unknown),Muriel Debois,Michel Janssens,Geert Leroux‐Roels,(unknown),Sheetal Sawant,Nicole L. Yates,Georgia D. Tomaras,Isabel Leroux‐Roels,François Roman	3
5	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial 2016 ·Current Opinion in Virology ·Ying Huang,(unknown),Carlos A. DiazGranados,Holly Janes,(unknown),(unknown),Allan C. deCamp,Barbara Metch,Shannon Grant,Brittany Sanchez,Sanjay Phogat,Marguerite Koutsoukos,Niranjan Kanesa-thasan,Patricia Bourguignon,Alix Collard,Susan Buchbinder,Georgia D. Tomaras,M. Juliana McElrath,Glenda Gray,James G. Kublin,Lawrence Corey,Peter B. Gilbert	7
6	Heterologous Prime-Boost Regimens with a Recombinant Chimpanzee Adenoviral Vector and Adjuvanted F4 Protein Elicit Polyfunctional HIV-1-Specific T-Cell Responses in Macaques 2015 ·PLoS ONE ·Clarisse Lorin,Yannick Vanloubbeeck,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Marguerite Koutsoukos,Pascal Mettens,Joe Cohen,Gérald Voss	9
7	Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients 2014 ·Journal of Immunological Methods ·Patricia Bourguignon,Frédéric Clément,(unknown),(unknown),Marguerite Koutsoukos,Wivine Burny,Philippe Moris,Clarisse Lorin,Alix Collard,Geert Leroux‐Roels,François Roman,Michel Janssens,Linos Vandekerckhove	17
8	Immunogenicity of a recombinant measles HIV-1 subtype C vaccine 2013 ·Vaccine ·Richard Stebbings,Bo Li,Clarisse Lorin,Marguerite Koutsoukos,Michèle Février,Edward Mee,Mark Page,Neil Almond,Frédéric Tangy,Gérald Voss	17
9	Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: A randomised placebo-controlled study 2013 ·Vaccine ·Thomas Harrer,Andreas Plettenberg,Keikawus Arastéh,Jan van Lunzen,Gerd Fätkenheuer,Hans Jaeger,Michel Janssens,Wivine Burny,Alix Collard,François Roman,A Loeliger,Marguerite Koutsoukos,Patricia Bourguignon,Ludo Lavreys,Gérald Voss	15
10	Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques 2012 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Clarisse Lorin,Lawrence Segal,Johann Mols,Danielle Morelle,Patricia Bourguignon,(unknown),Pascal Mettens,(unknown),(unknown),(unknown),Marguerite Koutsoukos,Gérald Voss,Frédéric Tangy	18
11	Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems 2010 ·Vaccine ·Isabel Leroux‐Roels,Marguerite Koutsoukos,Frédéric Clément,Sophia Steyaert,Michel Janssens,Patricia Bourguignon,Kristen W. Cohen,Marcus Altfeld,Pierre Vandepapelière,Louise Pedneault,Lisa McNally,Geert Leroux‐Roels,Gérald Voss	56
12	The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans 2009 ·Human Vaccines ·(unknown),(unknown),(unknown),Opokua Ofori‐Anyinam,(unknown),(unknown),Marguerite Koutsoukos,Philippe Moris,Daniel Cain,Marie‐Claude Dubois,Joe Cohen,W. Ripley Ballou	89
13	Acute-phase CD4+ T-cell proliferation and CD152 upregulation predict set-point virus replication in vaccinated simian–human immunodeficiency virus strain 89.6p-infected macaques 2009 ·Journal of General Virology ·Gerrit Koopman,Daniëlla Mortier,Sam Hofman,Marguerite Koutsoukos,Willy Bogers,Britta Wahrén,Gérald Voss,Jonathan L. Heeney	4
14	Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers 2008 ·Vaccine ·Pierre Vandepapelière,Yves Horsmans,Philippe Moris,Marcelle Van Mechelen,Michel Janssens,Marguerite Koutsoukos,Pascale Van Belle,Frédéric Clément,Emmanuel Hanon,Martine Wettendorff,Nathalie Garçon,Geert Leroux‐Roels	168
15	Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial 2007 ·Trials ·Eusébio Macete,Jahit Sacarlal,John J. Aponte,Amanda Leach,Margarita M. Navia,Jessica Milman,Caterina Guinovart,Inácio Mandomando,(unknown),Marc Lievens,Alex Owusu‐Ofori,Marie‐Claude Dubois,(unknown),Marguerite Koutsoukos,(unknown),Ricardo Thompson,Filip Dubovsky,W. Ripley Ballou,Joe Cohen,Pedro L. Alonso	25
16	Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers 2006 ·Vaccine ·Paul A. Goepfert,Georgia D. Tomaras,Helen Horton,David C. Montefiori,Guido Ferrari,(unknown),Gérald Voss,Marguerite Koutsoukos,Louise Pedneault,Pierre Vandepapelière,M. Juliana McElrath,Paul Spearman,Jonathan D. Fuchs,Beryl A. Koblin,William A. Blattner,Sharon E. Frey,Lindsey R. Baden,Clayton Harro,Thomas G. Evans	71
17	Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults 2004 ·Vaccine ·Pierre Vandepapelière,Barbara Rehermann,Marguerite Koutsoukos,Philippe Moris,Nathalie Garçon,Martine Wettendorff,Geert Leroux‐Roels	38
18	Seroprevalence of Herpes Simplex Virus Types 1 and 2 and Cytomegalovirus in Adolescents 1997 ·Clinical Infectious Diseases ·Susan L. Rosenthal,Lawrence R. Stanberry,Frank M. Biro,M. Slaoui,M Francotte,Marguerite Koutsoukos,Molly Hayes,David I. Bernstein	63
19	Polymorphonuclear neutrophils enhance anti-CD3-induced T cell activation: The role of polymorphonuclear FC-receptors 1991 ·Cellular Immunology ·Jacques Bentin,Marguerite Koutsoukos,M. Piérart,Thierry Appelboom,Jan Ceuppens	4
20	Immunopharmacological properties of RES-1080 in vitro 1990 ·Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Thierry Appelboom,Nicole Mairesse,M. Piérart,Marguerite Koutsoukos,Jacques Bentin	0

About Marguerite Koutsoukos

Marguerite Koutsoukos is a scholar working on Virology, Infectious Diseases and Immunology, having authored 29 papers that have together received 1.8k indexed citations. Recurring topics across this work include HIV Research and Treatment (18 papers), Immune Cell Function and Interaction (10 papers) and vaccines and immunoinformatics approaches (7 papers). The work is most often cited by research in Virology (1.0k citations), Immunology (929 citations) and Infectious Diseases (659 citations). Marguerite Koutsoukos has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Gérald Voss, Paul A. Goepfert, David C. Montefiori, Jesus F. Salazar-Gonzalez, Xiping Wei, Julie M. Decker, John R. Mascola, Miroslawa Bilska, Leonidas Stamatatos and Beatrice H. Hahn. Their work appears in journals such as Nature Communications, SHILAP Revista de lepidopterología and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact